Overview

A Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Participants With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or Mild Alzheimer's Disease Dementia

Status:
Not yet recruiting
Trial end date:
2026-12-14
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to characterize the dose-response for change from Baseline to Week 76 using Clinical Dementia Rating-Sum of Boxes (CDR-SB). The secondary objectives of the study are to test the superiority of at least one dose arm of BIIB080 versus placebo in change from Baseline to Week 76 using CDR-SB, to evaluate the efficacy of BIIB080 versus placebo in change from Baseline to Week 76 and to evaluate the safety and tolerability of BIIB080 in participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or with mild AD dementia.
Phase:
Phase 2
Details
Lead Sponsor:
Biogen